Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavrilimumab in Giant Cell Arteritis
NCT03827018Phase 2Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Sep 2018
- Primary completion
- Aug 2020
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in giant cell arteritis (GCA) comparing Mavrilimumab Arm with Placebo Arm (2 arms). Primary endpoint: Time to Flare by Week 26. Started Sep 2018; status: completed.
02
Drugs
mavrilimumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on NCT03827018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827018.